Miklós Nyíri December 18, 2016

Confidence Assay clinical study is Choice Contect on IJC Facebook page

+++CHOICE CONTENTS +++ Recommended by our Editors:

“Performance of a New HPV and Biomarker Assay in Management of hrHPV Positive Women”, by Kocsis, A., Takács, T., Jeney, C., Schaff, Z., Koiss, R., Járay, B., Sobel, G., Pap, K., Székely, I., Ferenci, T., Lai, H.-C., Nyíri, M. and Benczik, M.
Int J Cancer. 2016 Nov 22. doi: 10.1002/ijc.30534.…/10.1002/ijc.30534/abstract

Combining DNA methylation biomarker detection with high-risk human papillomavirus (hrHPV) testing is a promising screening option for cervical cancer. Currently, one of the largest clinical studies designed to evaluate human epigenetic biomarker testing for cervical screening is the Triage and Risk Assessment of Cervical Precancer by Epigenetic Biomarker (TRACE) study. In this TRACE analysis, methylation of the POU4F3 promoter, a candidate marker for high-grade HPV-positive cervical intraepithelial lesions (CIN3+), showed significantly higher sensitivity and similar specificity for CIN3+ when compared to liquid-based cytology. The findings suggest that quantitative methylation of POU4F3 is a valuable tool for high-grade CIN detection.

KEYWORDS: POU4F3 biomarker; cervical cancer; epigenetics; high risk HPV; host-gene methylation